Loading...

Marinus Pharmaceuticals

DB:0MV
Snowflake Description

Excellent balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0MV
DB
$236M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The last earnings update was 17 days ago. More info.


Add to Portfolio Compare Print
  • Marinus Pharmaceuticals has significant price volatility in the past 3 months.
0MV Share Price and Events
7 Day Returns
1.4%
DB:0MV
-2.6%
DE Pharmaceuticals
-0.2%
DE Market
1 Year Returns
6.7%
DB:0MV
-29.1%
DE Pharmaceuticals
-10.4%
DE Market
0MV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Marinus Pharmaceuticals (0MV) 1.4% 17% 29.1% 6.7% 0.8% -
DE Pharmaceuticals -2.6% -4.4% -9.9% -29.1% -20.2% 5.4%
DE Market -0.2% -2.1% 4.2% -10.4% 11.1% 10.6%
1 Year Return vs Industry and Market
  • 0MV outperformed the Pharmaceuticals industry which returned -29.1% over the past year.
  • 0MV outperformed the Market in Germany which returned -10.4% over the past year.
Price Volatility
0MV
Industry
5yr Volatility vs Market

Value

 Is Marinus Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Marinus Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €4.053.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Marinus Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Marinus Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0MV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.98
NasdaqGM:MRNS Share Price ** NasdaqGM (2019-05-17) in USD $4.5
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 27.4x
Germany Market PE Ratio Median Figure of 426 Publicly-Listed Companies 20.24x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Marinus Pharmaceuticals.

DB:0MV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:MRNS Share Price ÷ EPS (both in USD)

= 4.5 ÷ -0.98

-4.57x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Marinus Pharmaceuticals is loss making, we can't compare its value to the DE Pharmaceuticals industry average.
  • Marinus Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Marinus Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:0MV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.57x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
65.4%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.93x
Germany Market PEG Ratio Median Figure of 277 Publicly-Listed Companies 1.51x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Marinus Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Marinus Pharmaceuticals's assets?
Raw Data
DB:0MV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $1.10
NasdaqGM:MRNS Share Price * NasdaqGM (2019-05-17) in USD $4.5
Germany Pharmaceuticals Industry PB Ratio Median Figure of 9 Publicly-Listed Pharmaceuticals Companies 2.3x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.79x
DB:0MV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:MRNS Share Price ÷ Book Value per Share (both in USD)

= 4.5 ÷ 1.10

4.1x

* Primary Listing of Marinus Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Marinus Pharmaceuticals is overvalued based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Marinus Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Marinus Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Marinus Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
65.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Marinus Pharmaceuticals expected to grow at an attractive rate?
  • Marinus Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Marinus Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Marinus Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:0MV Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0MV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 65.4%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 18.2%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 3.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0MV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0MV Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 484 188 596 3
2022-12-31 244 19 336 3
2021-12-31 11 -102 -96 5
2020-12-31 8 -87 -65 7
2019-12-31 3 -27 -57 8
DB:0MV Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 -33 -43
2018-12-31 -28 -37
2018-09-30 -23 -31
2018-06-30 -19 -24
2018-03-31 -18 -19
2017-12-31 -19 -19
2017-09-30 -20 -20
2017-06-30 -24 -22
2017-03-31 -26 -27
2016-12-31 -25 -29
2016-09-30 -24 -30
2016-06-30 -23 -29

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Marinus Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Marinus Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0MV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Marinus Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0MV Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 6.35 10.39 2.30 2.00
2022-12-31 3.53 6.90 0.15 2.00
2021-12-31 -1.16 -0.79 -1.55 3.00
2020-12-31 -0.92 -0.49 -1.25 7.00
2019-12-31 -0.96 -0.55 -1.26 8.00
DB:0MV Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.98
2018-12-31 -0.90
2018-09-30 -0.87
2018-06-30 -0.74
2018-03-31 -0.68
2017-12-31 -0.80
2017-09-30 -0.90
2017-06-30 -1.10
2017-03-31 -1.36
2016-12-31 -1.47
2016-09-30 -1.60
2016-06-30 -1.63

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Marinus Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Marinus Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Marinus Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Marinus Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Marinus Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Marinus Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Marinus Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Marinus Pharmaceuticals's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Marinus Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Marinus Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0MV Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -43.21 9.47 33.14
2018-12-31 -36.73 8.99 28.19
2018-09-30 -31.35 8.49 23.35
2018-06-30 -24.41 7.99 16.85
2018-03-31 -19.46 7.34 12.43
2017-12-31 -18.90 6.97 12.08
2017-09-30 -20.18 6.89 13.14
2017-06-30 -22.47 6.85 15.34
2017-03-31 -26.87 6.75 19.78
2016-12-31 -28.64 6.54 21.71
2016-09-30 -30.24 6.30 23.51
2016-06-30 -28.74 6.15 22.14
2016-03-31 -25.06 5.82 18.80
2015-12-31 -24.85 5.62 18.82
2015-09-30 -20.84 5.53 14.96
2015-06-30 -17.92 5.00 13.07
2015-03-31 -17.08 4.21 11.96
2014-12-31 -13.38 3.28 8.64
2014-09-30 -12.21 2.22 7.63
2014-06-30 -12.43 1.68 7.06
2014-03-31 -10.62 1.59 5.53
2013-12-31 -9.07 1.26 4.12
2012-12-31 0.10 -3.59 0.70 0.83

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Marinus Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Marinus Pharmaceuticals has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Marinus Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Marinus Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Marinus Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Marinus Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Marinus Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Marinus Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Marinus Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Marinus Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 18.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Marinus Pharmaceuticals Company Filings, last reported 1 month ago.

DB:0MV Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 57.75 3.41 60.85
2018-12-31 68.33 0.00 72.73
2018-09-30 35.12 0.00 39.63
2018-06-30 45.02 0.00 46.37
2018-03-31 53.13 0.00 52.02
2017-12-31 58.01 0.00 53.39
2017-09-30 62.10 0.00 42.97
2017-06-30 16.29 3.50 20.28
2017-03-31 19.25 4.37 24.76
2016-12-31 21.48 5.24 30.10
2016-09-30 26.69 6.12 36.57
2016-06-30 32.33 7.12 44.02
2016-03-31 40.57 7.24 51.20
2015-12-31 46.92 7.36 56.20
2015-09-30 25.66 7.50 33.00
2015-06-30 29.88 7.00 39.93
2015-03-31 34.73 7.00 45.47
2014-12-31 41.15 7.00 49.72
2014-09-30 44.23 2.00 47.11
2014-06-30 4.48 2.00 8.42
2014-03-31 8.54 0.00 8.83
2013-12-31 9.46 0.00 10.04
2012-12-31 4.18 2.67 8.63
  • Marinus Pharmaceuticals's level of debt (5.9%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.3% vs 5.9% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Marinus Pharmaceuticals has sufficient cash runway for 1.8 years based on current free cash flow.
  • Marinus Pharmaceuticals has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 4.2% each year.
X
Financial health checks
We assess Marinus Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Marinus Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Marinus Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Marinus Pharmaceuticals dividends.
If you bought €2,000 of Marinus Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Marinus Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Marinus Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0MV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3.2%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0MV Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Marinus Pharmaceuticals has not reported any payouts.
  • Unable to verify if Marinus Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Marinus Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Marinus Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Marinus Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Marinus Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Marinus Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Marinus Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Marinus Pharmaceuticals has no CEO, or we have no data on them.
Management Team

Scott Braunstein

TITLE
Executive Chairman
COMPENSATION
$210K
AGE
55

Ed Smith

TITLE
VP, CFO
COMPENSATION
$501K
AGE
47
TENURE
5.5 yrs

Lorianne Masuoka

TITLE
Chief Medical Officer
COMPENSATION
$501K
AGE
57
TENURE
2.1 yrs

Lisa Caperelli

TITLE
Executive Director of Investor & Strategic Relations

TJ Lyons

TITLE
Vice President of Corporate

Kim McCormick

TITLE
Head of Regulatory Affairs
Board of Directors Tenure

Average tenure and age of the Marinus Pharmaceuticals board of directors in years:

2.5
Average Tenure
58.5
Average Age
  • The average tenure for the Marinus Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Scott Braunstein

TITLE
Executive Chairman
COMPENSATION
$210K
AGE
55
TENURE
0.3 yrs

Nicole Vitullo

TITLE
Independent Director
COMPENSATION
$55K
AGE
61
TENURE
13.7 yrs

Tim Mayleben

TITLE
Lead Independent Director
COMPENSATION
$79K
AGE
57
TENURE
2.3 yrs

Seth H. Fischer

TITLE
Director
COMPENSATION
$50K
AGE
62
TENURE
2.7 yrs

Enrique Carrazana

TITLE
Independent Director
COMPENSATION
$169K
AGE
56
TENURE
5.5 yrs

Mike Dougherty

TITLE
Director
COMPENSATION
$53K
AGE
60
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
30. Jan 19 Sell Edward Smith Individual 29. Jan 19 29. Jan 19 -2,492 €2.68 €-6,674
30. Jan 19 Sell Christopher Cashman Individual 28. Jan 19 28. Jan 19 -8,142 €2.74 €-22,281
X
Management checks
We assess Marinus Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Marinus Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ganaxolone product candidate exhibits anti-seizure, anti-depression, and anti-anxiety actions through its effects on synaptic and extrasynaptic GABAA receptors. It is also developing ganaxolone for cyclin-ependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, postpartum depression, refractory status epilepticus, and other indications. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.

Details
Name: Marinus Pharmaceuticals, Inc.
0MV
Exchange: DB
Founded: 2003
$211,900,248
52,554,625
Website: http://www.marinuspharma.com
Address: Marinus Pharmaceuticals, Inc.
170 North Radnor Chester Road,
Suite 250,
Radnor,
Pennsylvania, 19087,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM MRNS Common Stock Nasdaq Global Market US USD 01. Aug 2014
DB 0MV Common Stock Deutsche Boerse AG DE EUR 01. Aug 2014
LSE 0JYL Common Stock London Stock Exchange GB USD 01. Aug 2014
BMV MRNS * Common Stock Bolsa Mexicana de Valores MX MXN 01. Aug 2014
Number of employees
Current staff
Staff numbers
29
Marinus Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/18 22:34
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/06
Last earnings filing: 2019/05/01
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.